Advanced

188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment.

Altai, Mohamed; Wållberg, Helena; Honarvar, Hadis; Strand, Joanna; Orlova, Anna; Varasteh, Zohreh; Sandström, Mattias; Löfblom, John; Larsson, Erik LU and Strand, Sven-Erik LU , et al. (2014) In Journal of Nuclear Medicine 55(11). p.1842-1848
Abstract
Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate (188)Re-ZHER2:V2 as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Nuclear Medicine
volume
55
issue
11
pages
1842 - 1848
publisher
Society of Nuclear Medicine
external identifiers
  • pmid:25278516
  • wos:000344209200015
  • scopus:84910602926
ISSN
0161-5505
DOI
10.2967/jnumed.114.140194
language
English
LU publication?
yes
id
3dbd1516-e264-4003-980a-728367ec77a5 (old id 4738407)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25278516?dopt=Abstract
date added to LUP
2014-11-05 19:11:56
date last changed
2017-11-19 03:24:41
@article{3dbd1516-e264-4003-980a-728367ec77a5,
  abstract     = {Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate (188)Re-ZHER2:V2 as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.},
  author       = {Altai, Mohamed and Wållberg, Helena and Honarvar, Hadis and Strand, Joanna and Orlova, Anna and Varasteh, Zohreh and Sandström, Mattias and Löfblom, John and Larsson, Erik and Strand, Sven-Erik and Lubberink, Mark and Ståhl, Stefan and Tolmachev, Vladimir},
  issn         = {0161-5505},
  language     = {eng},
  number       = {11},
  pages        = {1842--1848},
  publisher    = {Society of Nuclear Medicine},
  series       = {Journal of Nuclear Medicine},
  title        = {188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment.},
  url          = {http://dx.doi.org/10.2967/jnumed.114.140194},
  volume       = {55},
  year         = {2014},
}